Indications and Purposes
| 1 Indications And Usage Sutent Is A Kinase Inhibitor Indicated For: The Treatment Of Gastrointestinal Stromal Tumor (Gist) After Disease Progression On Or Intolerance To Imatinib Mesylate. ( 1.1 ) The Treatment Of Advanced Renal Cell Carcinoma (Rcc). ( 1.2 ) The Adjuvant Treatment Of Adult Patients At High Risk Of Recurrent Rcc Following Nephrectomy. ( 1.3 ) The Treatment Of Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors (Pnet) In Patients With Unresectable Locally Advanced Or Metastatic Disease. ( 1.4 ) 1.1 Gastrointestinal Stromal Tumor (Gist) Sutent Is Indicated For The Treatment Of Gastrointestinal Stromal Tumor After Disease Progression On Or Intolerance To Imatinib Mesylate. 1.2 Advanced Renal Cell Carcinoma (Rcc) Sutent Is Indicated For The Treatment Of Advanced Renal Cell Carcinoma. 1.3 Adjuvant Treatment Of Renal Cell Carcinoma (Rcc) Sutent Is Indicated For The Adjuvant Treatment Of Adult Patients At High Risk Of Recurrent Rcc Following Nephrectomy. 1.4 Advanced Pancreatic Neuroendocrine Tumors (Pnet) Sutent Is Indicated For The Treatment Of Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors In Patients With Unresectable Locally Advanced Or Metastatic Disease. |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 1 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Sunitinib Malate |
|
ZINC3964325 |